HPX Stock Overview Manufactures and sells pharmaceuticals in Japan. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hisamitsu Pharmaceutical Co., Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hisamitsu Pharmaceutical Historical stock prices Current Share Price JP¥25.20 52 Week High JP¥28.00 52 Week Low JP¥21.00 Beta 0.33 1 Month Change -2.33% 3 Month Change 5.00% 1 Year Change -5.97% 3 Year Change -17.65% 5 Year Change -41.12% Change since IPO 68.00%
Recent News & Updates
Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025 Nov 27
First half dividend of JP¥45.00 announced Nov 09
Second quarter 2025 earnings released: EPS: JP¥61.35 (vs JP¥56.25 in 2Q 2024) Oct 11
Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024 Aug 20
First quarter 2025 earnings released: EPS: JP¥63.89 (vs JP¥52.08 in 1Q 2024) Jul 15 Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025 See more updates
Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025 Nov 27
First half dividend of JP¥45.00 announced Nov 09
Second quarter 2025 earnings released: EPS: JP¥61.35 (vs JP¥56.25 in 2Q 2024) Oct 11
Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024 Aug 20
First quarter 2025 earnings released: EPS: JP¥63.89 (vs JP¥52.08 in 1Q 2024) Jul 15 Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025
Final dividend of JP¥45.00 announced Jun 13
Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024 May 29
Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million. May 24
Full year 2024 earnings released: EPS: JP¥182 (vs JP¥148 in FY 2023) Apr 12
Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024 Apr 11
Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024 Feb 28
Upcoming dividend of JP¥42.50 per share Feb 21
Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023) Jan 13 Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024
Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024 Nov 01
Second quarter 2024 earnings released: EPS: JP¥56.25 (vs JP¥61.11 in 2Q 2023) Oct 06
New minor risk - Share price stability Oct 02
Upcoming dividend of JP¥42.50 per share at 1.8% yield Aug 23
Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023 Aug 03
First quarter 2024 earnings released: EPS: JP¥52.08 (vs JP¥20.46 in 1Q 2023) Jul 14
Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million. Jul 14 Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024
Full year 2023 earnings released: EPS: JP¥148 (vs JP¥119 in FY 2022) May 30
Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023 May 28
Full year 2023 earnings released: EPS: JP¥148 (vs JP¥119 in FY 2022) Apr 14
Upcoming dividend of JP¥42.25 per share at 2.2% yield Feb 20
Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023 Feb 12
Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022) Jan 13 Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023
Less than half of directors are independent Nov 16
Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023 Nov 02
Second quarter 2023 earnings released: EPS: JP¥61.11 (vs JP¥32.30 in 2Q 2022) Oct 13
Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million. Oct 13 Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023
Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022 Aug 05
First quarter 2023 earnings released: EPS: JP¥20.46 (vs JP¥28.90 in 1Q 2022) Jul 09 Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023
Full year 2022 earnings released: EPS: JP¥119 (vs JP¥113 in FY 2021) Jun 02
Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022 May 14
Less than half of directors are independent Apr 27
Full year 2022 earnings released: EPS: JP¥122 (vs JP¥113 in FY 2021) Apr 08 Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023
Upcoming dividend of JP¥42.00 per share Feb 18 Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022 Jan 30
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Jan 19
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022 Jan 13
Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021) Oct 15
Upcoming dividend of JP¥42.00 per share Aug 23
First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021) Jul 09
Full year 2021 earnings released Jun 03
Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020) Apr 10
Hisamitsu Pharmaceutical Co., Inc. Provides Earnings Guidance for the Year Ending February 28, 2022 Apr 09
Upcoming Dividend of JP¥41.75 Per Share Feb 18
New 90-day high: €51.50 Feb 10
Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2021 Results on Apr 08, 2021 Feb 06
Revenue misses expectations Jan 18
Revenue misses expectations Jan 16
Revenue misses expectations Jan 14
Third quarter 2021 earnings released: EPS JP¥24.82 Jan 14
New 90-day high: €50.50 Dec 05
Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2021 Results on Jan 13, 2021 Nov 27
New 90-day high: €46.40 Nov 11
First half earnings released Oct 09
Semi-annual earnings released: Revenue misses expectations Oct 09
Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2021 Results on Oct 08, 2020 Aug 24
New 90-day low - €37.20 Jul 30 Shareholder Returns HPX DE Pharmaceuticals DE Market 7D 0.8% -2.2% -2.0% 1Y -6.0% -15.6% 6.9%
See full shareholder returns
Return vs Market: HPX underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is HPX's price volatile compared to industry and market? HPX volatility HPX Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: HPX has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HPX's weekly volatility (5%) has been stable over the past year.
About the Company Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders.
Show more Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary How do Hisamitsu Pharmaceutical's earnings and revenue compare to its market cap? HPX fundamental statistics Market cap €1.85b Earnings (TTM ) €89.80m Revenue (TTM ) €920.55m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HPX income statement (TTM ) Revenue JP¥150.19b Cost of Revenue JP¥65.45b Gross Profit JP¥84.73b Other Expenses JP¥70.08b Earnings JP¥14.65b
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 09, 2025
Earnings per share (EPS) 199.75 Gross Margin 56.42% Net Profit Margin 9.75% Debt/Equity Ratio 0.4%
How did HPX perform over the long term?
See historical performance and comparison Dividends
2.1% Current Dividend Yield When do you need to buy HPX by to receive an upcoming dividend? Hisamitsu Pharmaceutical dividend dates Ex Dividend Date Feb 27 2025 Dividend Pay Date May 26 2025 Days until Ex dividend 65 days Days until Dividend pay date 153 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 21:16 End of Day Share Price 2024/12/20 00:00 Earnings 2024/08/31 Annual Earnings 2024/02/29
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Toshiro Yoshinaga Aizawa Securities Co. Ltd. Ritsuo Watanabe BofA Global Research Hidemaru Yamaguchi Citigroup Global Markets Japan Inc.
Show 11 more analysts 
